USPTO serial 79033179
ARIDYS
Reviewed by CopyMark Law Group
Reg. 3423098Status 404
- Filing date
- Status date
- Registration date
- May 6, 2008
- Examiner
- GLASSER, CARYN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ARIDYS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William S. Frommer
William S. Frommer FROMMER LAWRENCE & HAUG LLP745 Fifth AvenueNEW YORK, NY 10151UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Non-medicated cosmetic preparations for treating frown lines and other specific facial wrinkles; non-medicated cosmetic preparations for treating glabellar frown lines, facial wrinkles, hyperfunctional facial wrinkles, human skin, its asymmetries and defects; non-medicated cosmetic preparations for treating baldness; injectable cosmetic preparations for treating frown lines, facial wrinkles, hyperfunctional facial wrinkles, human skin, its asymmetries and defects; non-medicated cosmetic preparations for use in cosmetic surgery; cosmetic preparations containing or including botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other derivatives for the treatment of frown lines, facial wrinkles, hyperfunctional facial wrinkles, human skin, its asymmetries and defects; soaps, namely, skin soap, liquid soap, perfumery, essential oils, cosmetics, and hair lotions; dentifrices | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations, namely, pharmaceutical preparations for use in the treatment of gastrointestinal diseases, laxatives and purgative agents; pharmaceutical preparations for in use in the treatment of cardiovascular diseases, circulatory disorders, cancer, neurological diseases, orthopedic disorders, urological diseases, hormonal disorders; pharmaceutical preparations for use in the treatment of blood diseases; pharmaceutical preparations for the treatment of diabetes and diabetes-related disorders; pharmaceutical preparations for the treatment of ophthalmological disorders; pharmaceutical preparations for the treatment of age-related disorders; pharmaceutical preparations for the treatment of cough; pharmaceutical preparations for use in the treatment of muscle disorders; pharmaceutical preparations for cosmetic purposes for the treatment of frown lines and other facial wrinkles, human skin and of imbalances and defects therein; pharmaceutical preparations for use in cosmetic surgery; pharmaceutical preparations for the treatment of pain, muscle spasm, hemifacial spasm, blepharospasm, dystonia, torticollis, cerebral palsy, articular pathologies, acne, headache, migraine, hyperhydrosis, myofascial pain, and hyperfunctional facial lines; pharmaceutical preparations for the treatment of frown lines and other facial wrinkles, human skin and of imbalances and defects therein; pharmaceutical preparations for the treatment of dermatological disorders namely scars and psoriasis ; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other derivatives for the treatment of frown lines and other facial wrinkles, human skin and of imbalances and defects therein; Veterinary preparations, namely, veterinary preparations for use in the treatment of gastrointestinal diseases, laxatives and purgative agents; veterinary preparations for use in the treatment of cardiovascular diseases and circulatory disorders; veterinary preparations for use in the treatment of neurological diseases; veterinary preparations for use in the treatment of urological diseases; veterinary preparations for use in the treatment of hormonal disorders; veterinary preparations for use in the treatment of blood diseases; veterinary preparations for use in the treatment of muscle disorders, all for use in domestic or farm animals | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by IPSEN PHARMA S.A.S.
- Other trademarks owned by Société de Conseils de Recherches; et d'Applications Scientifiques; (S.C.R.A.S.)
- Other trademarks owned by Société de Conseils de Recherches; et d'Applications Scientifiques; (S.C.R.A.S.)
- Other trademarks owned by Société de Conseils de Recherches; et d'Applications Scientifiques; (S.C.R.A.S.)
- Other trademarks in Class 003
- Other trademarks in Class 005
- Similar marks named ARIDYS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 10, 2015 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Jul 10, 2015 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Dec 12, 2014 | C71T | CANCELLED SECTION 71 | — |
| May 13, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 12, 2009 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 22, 2009 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Aug 25, 2008 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 25, 2008 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 6, 2008 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 6, 2008 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 19, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 30, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 14, 2008 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jan 14, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 14, 2008 | ALIE | ASSIGNED TO LIE | — |
| Jan 14, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 11, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 11, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 17, 2007 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Dec 14, 2007 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Dec 6, 2007 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 3, 2007 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Dec 3, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 30, 2007 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 30, 2007 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 25, 2007 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 25, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 25, 2007 | ALIE | ASSIGNED TO LIE | — |
| Sep 17, 2007 | PAPER RECEIVED | — | |
| Apr 5, 2007 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 16, 2007 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 16, 2007 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 15, 2007 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 14, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 8, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 5, 2007 | NWAP | NEW APPLICATION ENTERED | — |
| Jan 4, 2007 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |